flow semaglutide trial The rationale, design and baseline data of FLOW, a kidney outcomes with once-weekly in people with type 2 diabetes and chronic kidney disease flow trial semaglutide chronic kidney

Slinic acts as your dedicated partner, offering a bespoke experience through video consultations and continuous monitoring by registered Pharmacists

Enter semaglutide, one of a class of medicines the GLP-1-receptor agonists that imitate GLP-1, helping the body lower glucose (in the case of people with diabetes) and, researchers suspect, curb appetite (in the case of people living with obesity who may also have diabetes)

Although the CIs were wide because of the small number of events in subgroups, point estimates showed that the combination of GLP-1RAs and SGLT2is tended to reduce the incidence of HHF more than either alone

2017 Sep;24(6):1410-1417

J.F., C.V., L.M., R.H.Z